Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.
- Home |
- Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3
Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3
- May 27, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
